ACAD Market Cap History
Below is a table of the ACAD market cap history going back to 3/1/2010:

Date ACAD Market Cap
3/1/201050.98M
4/30/201063.64M
7/31/201046.81M
10/29/201029.87M
3/1/201174.25M
4/30/2011144.95M
7/31/201186.06M
10/31/201164.95M
3/1/201287.29M
4/30/201279.39M
7/31/201285.38M
10/31/2012133.06M
3/1/2013500.90M
4/29/20131.04B
7/31/20131.75B
10/31/20132.07B
1/31/20142.13B
4/30/20141.99B
7/31/20142.02B
10/31/20142.76B
1/30/20153.05B
4/30/20153.43B
7/31/20154.92B
10/30/20153.51B
1/29/20162.33B
4/28/20163.67B
7/29/20164.22B
10/31/20162.82B
1/31/20174.20B
5/3/20173.96B
7/31/20173.64B
10/31/20174.33B
1/31/20183.73B
4/30/20181.97B
7/31/20181.89B
10/31/20182.44B
1/31/20193.28B
4/24/20193.47B

Also see: ACAD Shares Outstanding History
and ACAD YTD Return
ACAD Historical Market Cap:
+58.58% CAGR
ACAD Historical Market Cap: +58.58% CAGR

Mouse over chart for data details
3/1/2010 ...4/24/2019
Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders. Co.'s portfolio of products includes its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors. In addition to PD Psychosis, Co.'s pipeline includes multiple product opportunities being explored in clinical development across several CNS disorders. We show 38 historical shares outstanding datapoints in our ACAD shares outstanding history coverage, used to compute ACAD market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ACAD market cap history over the course of time is important for investors interested in comparing ACAD's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ACAD versus a peer is one thing; comparing ACAD market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ACAD can fluctuate over the course of history. With this page we aim to empower investors researching ACAD by allowing them to research the ACAD market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ACAD:
ACAD SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acadia Pharmaceuticals (ACAD) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

ACER Market Cap History
ACET Market Cap History
ACHC Market Cap History
ACHN Market Cap History
ACHV Market Cap History
ACOR Market Cap History
ACRS Market Cap History
ACRX Market Cap History
ACST Market Cap History
ADMA Market Cap History
More Healthcare companies »

 

ACAD Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.